NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Capsida Biotherapeutics

Capsida Biotherapeutics

Private
Thousand Oaks, CaliforniaHealthcare & Life Scienceshttps://capsida.com/

Last Round

Strategic

Feb 23, 2023

Total Funding Raised

$185M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Capsida Biotherapeutics is a biotechnology company that develops targeted gene therapies aimed at treating debilitating and life-threatening genetic disorders through an advanced adeno-associated virus (AAV) engineering platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

gene therapyAAV engineeringadeno-associated virusAAVcapsid engineeringgenetic medicineCNS gene therapyocular gene therapybiotech platformtargeted deliverydrug discoverygene therapy manufacturingAI-enabled biotechin vivo gene therapynext-gen therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Capsida Biotherapeutics Comparables

Compare Capsida Biotherapeutics with similar companies based on industry and business-model similarity.

Capsida Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Latus Bio
89%
Coave Therapeutics
85%
Apertura Gene Therapy
85%

Capsida Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicFeb 23, 2023
StrategicJan 4, 2023
Series AApr 29, 2021

Key People

Founding team and executive leadership

Julie Hakim

Chief Financial Officer

Executive Team

Capsida Biotherapeutics Investors

Notable investors and investment history

Capsida Biotherapeutics investors
InvestorRounds
Westlake Village BioPartnersSeries A
Versant VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors increased 77% MoM.

  • May 14, 2025

    Presented at the 28th Annual Meeting of the American Society of Gene & Cell Therapy.

Capsida Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Capsida Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Capsida Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersThousand Oaks, California
Employee Range47
Year Founded2019
Last FundingFeb 23, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.